A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Description

This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of RO7759065 as a single agent (Phase Ia) or in combination with atezolizumab (Phase Ib) in patients with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Several key aspects of the study design and study population are summarized below.

Conditions

Solid Tumour

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of RO7759065 as a single agent (Phase Ia) or in combination with atezolizumab (Phase Ib) in patients with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Several key aspects of the study design and study population are summarized below.

A Phase Ia/Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Condition
Solid Tumour
Intervention / Treatment

-

Contacts and Locations

Duarte

City of Hope Comprehensive Cancer Center, Duarte, California, United States, 91010

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Life expectancy at least 12 weeks
  • * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • * Adequate hematologic and end-organ function
  • * Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1
  • * Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
  • * Availability of representative tumor specimens required for patients in select cohorts.
  • * Women who are pregnant or breastfeeding
  • * Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, and/or radiotherapy, within 3 weeks prior to initiation of study treatment
  • * Active hepatitis B or C or tuberculosis
  • * Positive test for human immunodeficiency virus (HIV) infection
  • * Acute or chronic active Epstein-Barr virus (EBV) infection at screening
  • * Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first RO7759065 infusion
  • * Primary, untreated, or active central nervous system (CNS) metastases
  • * Active or history of autoimmune disease or immune deficiency
  • * Prior allogeneic stem cell or organ transplantation
  • * Any history of a Grade 3 immune-mediated adverse event attributed to prior cancer immunotherapy that resulted in permanent discontinuation of that agent
  • * Any history of a Grade 4 immune-mediated adverse event attributed to prior cancer immunotherapy.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Genentech, Inc.,

Study Record Dates

2027-02-28